79,902 Shares in Takeda Pharmaceutical Co. $TAK Purchased by Point Nemo Capital LLC

Posted by Geri Gentry on Nov 8th, 2026

Point Nemo Capital LLC bought a new stake in Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 79,902 shares of the company’s stock, valued at approximately $1,453,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ethic Inc. increased its stake in Takeda Pharmaceutical by 19.5% in the third quarter. Ethic Inc. now owns 436,514 shares of the company’s stock valued at $7,940,000 after purchasing an additional 71,261 shares during the period. May Hill Capital LLC purchased a new stake in shares of Takeda Pharmaceutical in the third quarter valued at about $256,000. Commonwealth Equity Services LLC raised its holdings in shares of Takeda Pharmaceutical by 20.7% in the third quarter. Commonwealth Equity Services LLC now owns 27,282 shares of the company’s stock valued at $496,000 after buying an additional 4,684 shares during the last quarter. Ascent Group LLC raised its holdings in shares of Takeda Pharmaceutical by 19.5% in the third quarter. Ascent Group LLC now owns 19,996 shares of the company’s stock valued at $364,000 after buying an additional 3,262 shares during the last quarter. Finally, Pzena Investment Management LLC boosted its stake in shares of Takeda Pharmaceutical by 19.8% during the third quarter. Pzena Investment Management LLC now owns 45,310 shares of the company’s stock worth $824,000 after buying an additional 7,490 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on TAK. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 30th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

View Our Latest Analysis on TAK

Insider Transactions at Takeda Pharmaceutical

In other Takeda Pharmaceutical news, insider Giles Platford sold 55,617 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $20.90, for a total value of $1,162,395.30. Following the transaction, the insider directly owned 270,253 shares of the company’s stock, valued at approximately $5,648,287.70. The trade was a 17.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Andrew Plump sold 165,393 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $2,828,220.30. Following the transaction, the insider owned 766,569 shares of the company’s stock, valued at approximately $13,108,329.90. The trade was a 17.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 683,074 shares of company stock worth $12,143,571 over the last quarter. 0.04% of the stock is currently owned by corporate insiders.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $21.02 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $13.56 and a 12 month high of $21.73. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.15 and a quick ratio of 0.60. The business has a 50 day simple moving average of $19.12 and a 200-day simple moving average of $17.67. The stock has a market capitalization of $67.35 billion, a PE ratio of 27.65 and a beta of -0.02.

About Takeda Pharmaceutical

(Free Report)

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.

The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Takeda serves patients and healthcare providers in Japan and markets around the world.